Supporting biopharma decision-making in neurology
Valinor Discovery and Renew Biotechnologies have formed a strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders. Developed to improve the prediction of disease onset and therapeutic responses, the initiative will provide Valinor access to multimodal data sets derived from thousands of patients spanning Parkinsons disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and other neurological disorders to support the development of large foundation models.
The collaboration combines Valinor’s knowledge in machine learning with Renew’s expertise in quality-controlled clinical laboratory infrastructure, generating high-resolution multi-omics data from well-characterised patient samples.
Neurological drug development has remained challenging, despite advances in technology, due to the biological complexity of the central nervous system and the limited availability of clinically relevant human data. Integrating large longitudinal molecular datasets with advanced predictive modelling enables companies to address this gap.
The collaboration will involve Renew sourcing clinical samples and applying its native-read sequencing workflows within a quality-controlled translational environment, generating genomic and epigenomic data for downstream modelling. Valinor will deploy its proprietary machine learning architectures to identify disease-relevant patterns and predictive signatures of therapeutic response from the longitudinal, multimodal data.
Joshua Pacini, co-founder and CEO of Valinor, said, “Predictive models are crucially dependent, not only on the experience of the machine learning team, but also on the quality and relevance of the underlying training data. Renew delivers a rare combination of neurological domain expertise and access to high-quality, longitudinal molecular and clinical data that are relevant to drug development. Paired with our machine learning expertise, this collaboration will offer biopharma teams a stronger foundation to design clinical research programs with a higher likelihood of success.”
Chad Pollard, co-founder and CEO of Renew, said, “Neurology programs often slow or fail when the underlying disease biology is not fully understood. Our role is to define and de-risk disease-specific biological signals early, so downstream modelling and development decisions are built on validated biology.”
The partnership hopes to increase decision-making confidence, accelerate programs toward clinical milestones, and reduce research and development costs. The parties will jointly own the resulting datasets, with Valinor serving as the exclusive AI partner authorised to train models from the generated data.
